About NOVODX
NOVODX is a Healthcare company based in Boca Raton (United States) founded in 2022. It operates as a point-of-care diagnostic tests are developed for in-home and clinical use. NOVODX has raised $1.2 million across 2 funding rounds. Its chief executive is Nancy Torres Kaufman. NOVODX offers products and services including GoldN Reader and Health Tests. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified. Its legal entity is Novo DX Corporation. Its competitors include Access Bio, SD Biosensor, Lumos Diagnostics, Fluxergy and Module Innovations and 4 more; 4 of its 9 listed competitors have raised funding.
Company details
NOVODX was founded in 2022 in Boca Raton, United States, within the diagnostics sector. Point-of-care tests are developed for over-the-counter self-testing at home and professional use in clinics. Reusable quantitative and qualitative meters are employed to replicate clinical laboratory results. Applications cover respiratory diseases, infectious conditions, and aspects of mens and womens health.
- Headquarters Boca Raton, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website novo-dx.com
- Social LinkedIn
- Legal Name Novo Dx Corporation
- Total Equity Funding$1.2M (USD)
in 2 rounds
- Latest Funding Round$200K (USD), Seed
Mar 2025
Products & Services of NOVODX
NOVODX offers a comprehensive portfolio of products and services, including GoldN Reader and Health Tests.
Reusable tool for quick at-home tests of health indications.
Rapid testing kits for conditions like thyroid and COVID.
Funding Insights of NOVODX
NOVODX has successfully raised a total of $1.2M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $200 thousand completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.2M
- Total Rounds 2
- Last Round Seed — $200,000
- First Round $1M
(Sep 2023)
All 2 funding rounds of NOVODX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $200,000 | Seed | – | – | – |
| Sep 2023 | $1M | Seed | – | – | – |
People of NOVODX
1 people are tracked at NOVODX (1 in leadership).
| Name | Role | Group |
|---|---|---|
Nancy Torres Kaufman | CEO | Leadership |
Complete people profiles for NOVODX
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NOVODX
3 dated milestones of NOVODX across 3 years, from founding to its latest funding, stage changes and deals.
- Founded NOVODX is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Seed, of $200K.
Competitors of NOVODX
NOVODX has 9 listed competitors in our database, 4 of them funded. They include Access Bio, SD Biosensor, Lumos Diagnostics, Fluxergy and Module Innovations, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| accessbio.net | 2001 | Somerset, United States | $22M | 52 | In vitro rapid diagnostic tests, biosensor, and molecular diagnostic products for diagnosis of infectious diseases. | |
| sdbiosensor.com | 2001 | Suwon-si, South Korea | – | – | Biosensors for point-of-care diagnostics are developed by SD Biosensor. | |
| lumosdiagnostics.com | 2017 | Carlsbad, United States | $40M | – | Diversified diagnostic assays and readers are developed for point-of-care use. | |
| fluxergy.com | 2011 | Irvine, United States | – | 74 | Provides diagnostic devices and software for clinical and veterinary point-of-care testing. | |
| moduleinnovations.com | 2014 | Pune, India | $799,890 | – | Diagnostics strip for bacterial detection | |
| dxgenco.com | 2016 | – | – | – | Point-of-care diagnostic products for diabetes and tuberculosis are provided. | |
| shanxmedtech.com | 2019 | Eindhoven, Netherlands | – | – | In vitro diagnostic platforms for antibiotic testing are provided. | |
| alantissciencesindia.com | 2020 | Manipal, India | – | – | Molecular biology and microbiology research services are provided for diagnostics. | |
| diasurebio.com | 2022 | Seoul, South Korea | $71,475 | – | Rapid antigen tests for infectious diseases are developed. |
Detailed competitors of NOVODX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as NOVODX (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NOVODX
NOVODX was founded in 2022 and raised its 1st funding round 1 year after it was founded.
NOVODX is headquartered in Boca Raton, United States. It is registered at Boca Raton, Florida, United States.
Nancy Torres Kaufman is the current CEO of NOVODX.
NOVODX is a funded company, having raised a total of $1.2M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Sep 2023.
NOVODX was founded in 2022 in Boca Raton, United States, within the diagnostics sector. Point-of-care tests are developed for over-the-counter self-testing at home and professional use in clinics. Reusable quantitative and qualitative meters are employed to replicate clinical laboratory results. Applications cover respiratory diseases, infectious conditions, and aspects of mens and womens health.
NOVODX's top competitors include Access Bio, SD Biosensor and Lumos Diagnostics.
NOVODX offers GoldN Reader and Health Tests.
NOVODX operates through Novo Dx Corporation.